• Leica Biosystems and RareCyte have announced the co-marketing of AccuCyte-CyteFinder rare cell analysis product line with Leica Biosystems' BOND RX research staining platform.
    Thursday, October 15, 2015

    RareCyte and Leica Biosystems Co-Market Slide-Based Assay for Fully Automated Immunostaining of  Circulating Tumor Cells

    New Partnership Advances Circulating Tumor Cell Detection 

    Melbourne, Australia & Seattle, WA, October, 15, 2015 – Leica Biosystems and RareCyte, Inc. (RareCyte) have announced the co-marketing of RareCyte's AccuCyte®-CyteFinder® rare cell analysis product line with Leica Biosystems' BOND RX research staining platform*.

    With this partnership researchers now have access to a fully automated solution for immuno-staining of captured circulating tumor cells (CTCs) deposited on microscope slides, providing a key step to accelerating the development of clinical application for CTCs.

    The RareCyte technology represents a major advancement in visual CTC detection, analysis, and single cell retrieval. By linking AccuCyte-CyteFinder with Leica Biosystems’ BOND RX platform, researchers will be able to easily collect CTCs and perform either immuno-histochemical (IHC) or immunofluorescence (IF) automated staining on a glass slide. With the CyteFinder automated image analysis system, cells may be analyzed in up to six IF channels for multiplexed phenotyping. This is followed by integrated single cell retrieval of identified CTCs for downstream analysis using technologies such as Next Generation Sequencing (NGS).

    RareCyte’s AccuCyte-CyteFinder is being used by leading institutions for research and investigational diagnostic development. The BOND RX platform is an open and flexible system that efficiently automates staining. It provides a high-throughput workflow with exceptional consistency and minimal hands-on time.

    "We are extremely pleased to partner with Leica Biosystems." said RareCyte CEO Ron Seubert. "This will enable us to provide an integrated platform that combines rare cell identification and single cell analysis capability. This agreement will help make CTC analysis available broadly to the scientific and diagnostic research community. It will further accelerate the investigation of potential blood-based cancer diagnostics."

    Mr. Ralf Eckert, VP Innovations at Leica Biosystems added: “We are happy that our platform is facilitating the immuno-staining of captured circulating tumor cells. We will continually evolve the BOND RX platform in order to provide researchers with enhanced tools and help speed-up important discoveries in cancer diagnostics."

    *For Research Use Only. Not for use in diagnostic procedures.

  • RareCyte Names Michael A. Nemzek as President
    Monday, August 24, 2015

    RareCyte Names Michael A. Nemzek as President  

    Nemzek brings decades of life science industry experience to new role.

    Seattle, WA – August 24, 2015  - RareCyte, a life science company that provides globally deployable solutions to identify, isolate and analyze rare cells, has named Michael A. Nemzek as its President. 

    “RareCyte is rapidly commercializing its technology and enhancing our leadership team is critical to our success,” said RareCyte CEO Ron Seubert. “We are delighted to have Mike join our company and excited to have him leading our key growth initiatives.”

    Nemzek comes most recently from Affymetrix, where he served as Vice President of Strategic Marketing and was responsible for developing and managing strategy, in-licensing, and product life cycle management. His efforts at Affymetrix contributed to dramatic growth in the company’s genotyping business. Nemzek’s leadership expertise extends throughout the new product introduction process and growing commercial operations. Prior to Affymetrix, Nemzek held various executive leadership roles successfully growing several early stage companies.

    “It is thrilling to join RareCyte in its work to bring customers an innovative technology platform that enables the analysis of rare cells across the spectrum of disease with the capability to deliver unprecedented insight into human health” said Nemzek. “I couldn't be more enthusiastic to build upon what Ron and his team have created to further drive success as the company moves to broader commercialization.”

    RareCyte believes that rare cells hold many of the answers to difficult human health questions. RareCyte’s novel platform is an integrated set of technologies that seamlessly leverages existing laboratory workflows. AccuCyte® collection technology stratifies blood components, comprehensively isolates nucleated cells, and transfers them to microscope slides. CyteFinder® scanning and image analysis enables rapid and accurate characterization of individual cells from the enriched samples. Single cells of interest can then be retrieved and collected by CyteFinder’s integrated CytePicker® module for genomic analysis using microarrays or next-generation sequencing.


  • AccuCyte & CyteFinder featured in Upcoming GenomeWeb Webinar on April 29
    Tuesday, April 21, 2015

    AccuCyte & CyteFinder featured in Upcoming GenomeWeb Webinar

    The webinar titled “Genomic Analysis of CTCs and cfDNA for Dynamic Monitoring of Tumors” will feature sequencing analysis on circulating tumor cells (CTCs) identified and retrieved by AccuCyte CyteFinder systems. The session highlights the cutting-edge cancer research being pursued by Anup Madan of Covance and C. Anthony Blau from the University of Washington.

    The webinar will take place on Wednesday, April 29 at 7 a.m. PDT/10 a.m. EDT.

    The content will include case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize genomic changes throughout cancer detection and treatment.

    Learn more and register for this webinar today!

  • RareCyte to Present Clinical Research with the AccuCyte - CyteFinder System for Identification, Characterization and Single Cell Molecular Analysis of Circulating Tumor Cells at AACR Conference
    Monday, April 20, 2015

     Seattle, WA USA, April 17, 2015 -- RareCyte Inc., a Seattle based life science company focused on characterizing and isolating rare cells in blood, announces the presentation of two studies featuring its AccuCyte® – CyteFinder® system at the American Association for Cancer Research (AACR) Annual Meeting.  The studies highlight the clinical performance and integrated single cell retrieval capability of AccuCyte – CyteFinder.  The conference will be held April 18-22 in Philadelphia. 

    The first study, “Clinical performance of the AccuCyte – CyteFinder system, a dual-technology platform for comprehensive collection and high resolution imaging of circulating tumor cells,” describes application of technology that combines comprehensive density-based collection of nucleated blood cells, transfer to microscope slides for automated staining, high-resolution digital scanning, image analysis and single-cell retrieval.  In a blinded investigation against the CellSearch® system, the only FDA-cleared CTC platform, blood samples from prostate, breast and lung cancer patients were tested.  AccuCyte – CyteFinder found either equivalent or considerably more CTCs and in lung cancer, AccuCyte – CyteFinder identified CTCs in several cases where CellSearch found none.

    The second study, “Comprehensive multi-omic analysis of circulating tumor cells isolated from a metastatic triple-negative breast cancer patient to identify pathogenic genomic aberrations,” was performed in collaboration with Covance Genomic Services.  The research objective was to investigate technologies that can be used for defining the genomic landscape of CTCs in order to assess genetic heterogeneity and determine how similar the molecular profile of individual CTCs is to metastatic tumors.  This study utilized RareCyte’s integrated CytePicker® retrieval device to collect individual CTCs from a patient with triple-negative breast cancer for subsequent genomic analysis by next generation sequencing methods. 

    “There is tremendous interest in the use of blood samples to monitor cancer by sequencing methods,” said Eric Kaldjian, CMO of RareCyte.  “But it will be essential to evaluate both cancer phenotype as well as genotype, to best understand cancer biology and treatment options. By transferring cells from blood to slide, AccuCyte transforms a liquid matrix into a solid one – individual CTCs are now ‘blood-borne tissue’ – which can be evaluated in all the same ways that cancer tissue samples are – visually by CyteFinder, or molecularly using CytePicker.”

    RareCyte CEO Ron Seubert says, “We feel that AACR is the perfect place to present these important studies. RareCyte is addressing the need for an integrated platform that combines both rare cell identification and single cell analysis capability in a practical laboratory workflow. AccuCyte – CyteFinder is a significant step toward a robust and accurate diagnostic CTC system for the clinical setting.”  

    The posters will be presented during the Circulating Tumor Cells session on Monday, April 20 from 8 a.m. to 12 p.m. in Section 23 at Poster Board Number 22 (Abstract Number 1601) and Poster Board Number 30 (Abstract Number 1609).

  • AACR 2015 Annual Meeting
    Saturday, April 18, 2015

    RareCyte will attend the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA April 18-22, 2015. Please stop by our poster titled, "Clinical performance of the AccuCyte® - CyteFinder® System, a dual-technology platform for comprehensive collection and high resolution imaging of circulating tumor cells" on Monday, April 20 from 8 a.m. to 12 p.m. in Section 23, Poster Board Number 22.